What Is Happening With Eli Lilly Stock?
Eli Lilly (LLY)’s stock skyrocketed nearly 50%, fueled not just by impressive earnings and a sharp margin boost, but also by hitting a $1T market cap and buzz around breakthrough GLP-1 and oral drug prospects. Let’s unpack the forces propelling this remarkable rally.
Below is an analytical breakdown of stock movement into key contributing metrics.
| 5252025 | 11212025 | Change | |
|---|---|---|---|
| Stock Price ($) | 711.1 | 1,059.7 | 49.0% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 49,003.2 | 53,258.1 | 8.7% |
| Net Income Margin (%) | 22.7% | 25.9% | 14.3% |
| P/E Multiple | 57.5 | 69.0 | 19.8% |
| Shares Outstanding (Mil) | 898.7 | 897.9 | 0.1% |
| Cumulative Contribution | 49.0% |
So what is happening here? The stock surged 49%, driven by an 8.7% revenue boost, a 14% rise in net margin, and a 20% jump in P/E multiple. Let’s dive into the key moves behind these gains.
Here Is Why Eli Lilly Stock Moved
- Merck Stock Pays Out $53 Bil – Investors Take Note
- Chevron Stock Hands $123 Bil Back – Worth a Look?
- Years of Rewards: $53 Bil From Coca-Cola Stock
- Intuitive Surgical Stock Near Crucial Support – Buy Signal?
- FactSet Research Systems Stock Pulls Back to Support – Smart Entry?
- Veeva Systems Stock Delivers Strong Cash Yield – Upside Ahead?
- 1T Market Cap Reached: Eli Lilly hit a $1 trillion market cap on Nov 21, first pharma to do so, driven by GLP-1 drugs.
- Strong Q3 Earnings: Q3 2025 revenue of $17.6B and non-GAAP EPS of $7.02 beat estimates, and 2025 guidance was raised.
- Strong Q2 Earnings: Q2 2025 revenue of $15.56B and adjusted EPS of $6.31 beat forecasts; full-year guidance raised.
- GLP-1 Drugs Success: High demand for Mounjaro and Zepbound drove significant revenue growth and market share.
- Oral Drug Anticipation: Anticipation for oral obesity drug Orforglipron’s early 2026 approval fueled future growth outlook.
Our Current Assesment Of LLY Stock
Opinion: We currently find LLY stock attractive but volatile. Why so? Have a look at the full story. Read Buy or Sell LLY Stock to see what drives our current opinion.
Risk: A good way to gauge risk in LLY is by checking how much it fell during major market downturns. It dropped about 43% in the Dot-Com Bubble and over 50% in the Global Financial Crisis. Even during less severe events like the 2018 Correction, Covid pandemic, and the recent Inflation Shock, the stock still dipped around 18-22%. So, while LLY might look solid on paper, history shows it’s not immune to sharp sell-offs when the market turns south.
LLY stock may have seen strong gains recently, but investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.